Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 14/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | FNTA | P49354 | 2/20 | 0.54 |
| ▸ | FNTB | P49356 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066083 | 1.00 | TRPM8 (1.00) | TRPM8HTR2AHTR2CFNTAFNTB | |
| SCHEMBL4066079 | 1.00 | TRPM8 (1.00) | TRPM8HTR2AHTR2CFNTAFNTB | |
| SCHEMBL4143746 | 0.91 | TRPM8 (0.92) | TRPM8 | |
| SCHEMBL4143742 | 0.91 | TRPM8 (0.92) | TRPM8 | |
| SCHEMBL3956663 | 0.89 | TRPM8 (0.80) | TRPM8HTR2AHTR2C | |
| SCHEMBL3956670 | 0.89 | TRPM8 (0.80) | TRPM8HTR2AHTR2C | |
| SCHEMBL3069687 | 0.88 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL3956643 | 0.88 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL3958128 | 0.88 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL3066469 | 0.88 | TRPM8 (1.00) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | claimed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | TRPM8 33/4885HTR2A 84/4885HTR2C 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.